Key Takeaways
- • The European Commission published revised draft Merger Guidelines on April 30, 2026, replacing guidance from 2004 and 2008, incorporating "competitiveness" and "resilience" as explicit analytical criteria aligned with the Draghi Report and broader EU industrial policy objectives.
- • The Commission introduces an "innovation shield" presuming acquisitions of small innovative firms and start-ups are low-risk absent credible evidence the target would become a material competitive constraint, significantly narrowing the "killer acquisition" doctrine to only dominant firms acquiring nascent rivals capable of becoming significant competitors.
- • The revised framework expands guidance on dynamic and forward-looking theories of harm—including innovation competition reduction, elimination of potential competitors, and ecosystem effects—while maintaining the Significant Impediment to Effective Competition (SIEC) test as the central analytical framework.
- • Efficiencies assessment maintains the same substantive test and burden of proof on merger parties, but now explicitly encompasses longer-term and non-cost benefits including sustainability, resilience, and innovation alongside traditional cost savings.
- • The Draft Guidelines subject to public consultation until June 26, 2026, and expected adoption by year-end, will reshape deal strategy by requiring broader risk screening for forward-looking harms and evidence-based "theories of benefit" with early stakeholder engagement.
Summary
The revision signals a meaningful policy reorientation toward a more dynamic, forward-looking approach that explicitly incorporates competitiveness and resilience considerations into EU merger control analysis. Critically, the Commission acknowledges that certain large-scale combinations may enhance competition—including creation of stronger European players—and that long-term effects like innovation and supply chain robustness warrant appropriate consideration within competitive assessment frameworks. This represents not a fundamental departure from the 2004 Merger Regulation but rather a modernization of analytical practice that has evolved through decisional precedent and court oversight.
A significant innovation is the introduction of an "innovation shield" that presumes acquisitions of small innovative firms and start-ups present low competitive risk absent credible evidence the target would have matured into a material competitive constraint. This substantially narrows the "killer acquisition" doctrine—previously applied broadly—to apply only where a dominant firm acquires a nascent rival capable of evolving into a significant competitor. This change addresses persistent concerns that overly restrictive acquisition policies inhibited innovation ecosystems. The Draft Guidelines simultaneously expand guidance on dynamic theories of harm, articulating how the Commission will assess non-price competition reductions, elimination of potential competitors, and ecosystem-level competitive effects.
The efficiencies framework maintains existing substantive tests and the merger parties' burden of proof but broadens scope to encompass non-cost, longer-term benefits including sustainability, resilience, and innovation capacity alongside traditional cost savings. While practical impact may remain limited for problematic transactions, the guidance enables earlier proactive engagement with the Commission on efficiency narratives. Additionally, the revision restricts Member States' ability to invoke legitimate interests—narrowly defined as public security, media plurality, and financial stability—to intervene in Commission-exclusive merger reviews, requiring clear evidence-based justifications and prohibiting disproportionate or discriminatory measures masking protectionist aims.
For dealmakers, the revised framework necessitates broader risk screening for forward-looking competitive harms beyond traditional innovation pipeline analysis, coupled with early development of robust "theories of benefit" grounded in empirical evidence. Deal strategy will increasingly require early internal modeling, third-party evidence documentation, and proactive stakeholder engagement with customers and suppliers. The Draft Guidelines enter public consultation through June 26, 2026, with expected final adoption by year-end, likely governing assessment of ongoing cases.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.